Recombinant Human Procalcitonin (Recombinant)

Added to your cart

Recombinant Human Procalcitonin (Recombinant)

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P742-1


Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. It is secreted by a variety of different cells from numerous organs in response to proinflammatory stimulation. PCT has been identified as an important marker to use for the diagnosis and management of bacterial infections and sepsis. PCT is also extremely useful for physicians as it enables specific differentiation between a bacterial infection and any other causes of inflammatory reactions, (such as viral infections, allergies, autoimmune disease and graft rejection) which do not lead to a significant increase in PCT.


More information



  • Shipping Information
  • Dry Ice
  • Abbreviations
  • PCT
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -15°C
  • Buffer
  • 50mM NaH2PO4, pH7.5 containing 150mM NaCl
  • Presentation Matrix
  • Single homogenous batch, supplied lyophilised from 50mM NaH2PO4, pH 7.5, containing 150mM NaCl.
  • Purity/grade
  • >96%
  • Source
  • Expressed in E.coli
  • Molecular weight
  • 13kDa
  • Uniprot No.
  • P01258

Technical Documents

Certificates Of Analysis (164.48KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox